| Name | Title | Contact Details |
|---|---|---|
Tara D`Orsi |
Executive Vice President, General Counsel and Chief Compliance Officer | Profile |
Tara D'Orsi |
Executive Vice President, Chief Compliance Officer and General Counsel | Profile |
Isto Biologics is an orthobiologics company dedicated to helping patients heal faster through advanced solutions for spine, orthopedics, sports and regenerative medicine.
Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases.
Advancing orthobiologics to enhance the body’s ability to heal. Bioventus’ products are known for their safety, innovation, and effectiveness.
Trio Health offers a unique collaboration with clinical experts, patients and specialty pharmacies to allow unparalleled insight into patient care. Together with our advisory boards, we created Trio Health MDX, a proprietary system to collect and share information from all three stakeholders. This innovative collaboration provides the patient with unprecedented care thereby improving patient outcomes.
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company`s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company`s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.